Department of Cardiology, Tokyo General Hospital, 3-15-2 Egota, Nakano-ku, Tokyo, 165-8906, Japan.
Am J Cardiovasc Drugs. 2023 Mar;23(2):185-196. doi: 10.1007/s40256-023-00571-y. Epub 2023 Feb 4.
Diuretic response (DR) in patients with symptomatic acute decompensated heart failure (ADHF) has an impact on prognosis. This study aimed to identify predictive factors influencing acute 6 h poor DR and to assess DR after early administration of tolvaptan (TLV).
This multicenter retrospective study included 1670 patients who were admitted for ADHF and received intravenous furosemide within 1 h of presentation in clinical scenario 1 or 2 defined based on initial systolic blood pressure ≥100 mmHg with severe symptoms (New York Heart Association class III or IV (n = 830). The score for the poor DR factors in the very acute phase was calculated in patients treated with furosemide-only diuretics (n = 439). The DR to TLV administration was also assessed in patients who received an additional dose of TLV within 6 h (n = 391).
The time since discharge from the hospital for a previous heart failure < 3 months (odds ratio [OR] 2.78, 95% confidence interval [CI] 1.34-5.83; p = 0.006), loop diuretics at admission (OR 3.05, 95% CI 1.74-5.36; p < 0.0001), and estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m (OR 2.99, 95% CI 1.58-5.74; p = 0.0007) were independent determinants of poor DR. The frequency of poor DR according to the risk stratification group was low risk (no risk factor), 18.9%; middle risk (one risk factor), 33.1%; and high risk (two to three risk factors), 58.0% (p < 0.0001). All risk groups demonstrated a significantly lower incidence of poor DR with early TLV administration: 10.7% in the early TLV group versus 18.9% in the loop diuretics group (p = 0.09) of the low-risk group; 18.4% versus 33.1% (p = 0.01) in the middle-risk group, and 20.2% versus 58.0% (p < 0.0001) in the high-risk group.
Early administration of TLV in patients with predicted poor DR contributed to a significant diuretic effect and suppression of worsening renal function.
有症状的急性失代偿性心力衰竭(ADHF)患者的利尿剂反应(DR)对预后有影响。本研究旨在确定影响急性 6 小时不良 DR 的预测因素,并评估早期给予托伐普坦(TLV)后的 DR。
这是一项多中心回顾性研究,纳入了 1670 名因 ADHF 入院的患者,他们在临床情况 1 或 2 中于就诊后 1 小时内接受了静脉注射呋塞米,临床情况 1 或 2 基于初始收缩压≥100mmHg 且症状严重(纽约心脏协会心功能分级 III 或 IV 级(n=830)。在接受呋塞米单药利尿剂治疗的患者(n=439)中计算了非常急性阶段不良 DR 因素的评分。还评估了在 6 小时内接受额外 TLV 剂量的患者(n=391)的 TLV 给药后的 DR。
出院后 3 个月内因心力衰竭再次入院的时间<3 个月(优势比 [OR] 2.78,95%置信区间 [CI] 1.34-5.83;p=0.006)、入院时使用袢利尿剂(OR 3.05,95% CI 1.74-5.36;p<0.0001)和估算肾小球滤过率(eGFR)<45mL/min/1.73m(OR 2.99,95% CI 1.58-5.74;p=0.0007)是不良 DR 的独立决定因素。根据风险分层组的不良 DR 发生率低风险(无风险因素)为 18.9%;中风险(一个风险因素)为 33.1%;高风险(两个至三个风险因素)为 58.0%(p<0.0001)。所有风险组均显示早期 TLV 给药可显著降低不良 DR 的发生率:低风险组中早期 TLV 组为 10.7%,而袢利尿剂组为 18.9%(p=0.09);中风险组为 18.4%比 33.1%(p=0.01),高风险组为 20.2%比 58.0%(p<0.0001)。
对预测不良 DR 的患者早期给予 TLV 有助于产生显著的利尿作用并抑制肾功能恶化。